This notice is from the archives of The Notice Board. Information contained in this notice was accurate at the time of publication but may no longer be so.
The Alberta Diabetes Institute at the University of Alberta is pleased to announce a collaboration with Janssen Pharmaceuticals and its parent company Johnson & Johnson to advance early-stage technologies related to Type I and Type II diabetes. The Alberta Diabetes Institute - Johnson & Johnson Diabetes Research Fund is a $600,000 partnership between Alberta Diabetes Foundation, Janssen Inc. (Johnson & Johnson) and the Government of Alberta. The three year competitive fund, administered by U of A’s Alberta Diabetes Institute, will support research in either Type I or Type II diabetes with a focus on highly novel hypothesis-testing for targets, agents, therapies, diagnostics, etc., discovery research with a high potential for commercialization.
This is the third year of funding and this year's Letter of Intent due Monday, February 29, 2016 (register here). LOIs will be evaluated by a review committee that includes industry representation. This will be followed by invitation for full application. Up to a maximum of $50,000 for one year may be requested.
Visit http://adi.ualberta.ca/ADIandJJResearchFund for more information.
Timelines
- Letter of Intent due February 29, 2016 (register here)
- Notification of approval to submit full application April 4, 2016
- Full application due May 2, 2016
- Notification of funding May 31, 2016
Attached
- 2016 Call for LOIs
- News Release 2015 Awardees
Notes
- You do not have to be a member of the ADI to apply for this funding
- Forward this information to your research office, researchers, administrators, etc.
Contact:
Gillian Laird | gillian.laird@uleth.ca | (403) 329-2101
